Defining invasive fungal infection risk in hematological malignancies: a new tool for clinical practice

Main Article Content

Benedetta Rambaldi *
Domenico Russo
Livio Pagano
(*) Corresponding Author:
Benedetta Rambaldi | detta.rambaldi@hotmail.it


Downloads month by month

Downloads

Download data is not yet available.

Article Details

References

1. Pagano L, Akova M, Dimopoulos G, Herbrecht R, Drgona L, Blijlevens N. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. Journal of Antimicrobial Chemotherapy 2011: 66: i5-i14. http://jac.oxfordjournals.org/content/66/suppl_1/i5.abstract

2. Herbrecht R, Bories P, Moulin J-C, Ledoux M-P, Letscher-Bru Vr. Risk stratification for invasive aspergillosis in immunocompromised patients. Annals of the New York Academy of Sciences 2012:1272: 23-30. http://dx.doi.org/10.1111/j.1749-6632.2012.06829.x

3. Ananda-Rajah MR, Cheng A, Morrissey CO, et al. Attributable Hospital Cost and Antifungal Treatment of Invasive Fungal Diseases in High-Risk Hematology Patients: an Economic Modeling Approach. Antimicrobial Agents and Chemotherapy 201: 55: 1953-1960. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3088208/

4. Heimann SM, Vehreschild MJGT, Cornely OA, et al. A cost and resource utilization analysis of micafungin bridging for hemato-oncological high-risk patients undergoing allogeneic stem cell transplantation. European Journal of Haematology 2015: 94: 526-531. http://dx.doi.org/10.1111/ejh.12466

5. Pagano L, Busca A, Candoni A, et al. Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. Blood Reviews 2016. http://www.sciencedirect.com/science/article/pii/S0268960X16300753